To determine whether hPCa patients could benefit from IL-27's anti-tumor effects, we next immunohistochemically evaluated expression and distribution of IL-27R in prostate tissue sections from PCa patients following radical prostatectomy (RP). The gene discussed is IL27RA; the disease is neoplasm.